Skip to content

Effect of calendula officinalis on treatment of candida vaginitis

Comparing calendula officinalis and clotrimazole for treatment of candida vaginitis: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201309253706N20
Enrollment
124
Registered
2014-03-03
Start date
2014-03-03
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candida vaginitis. Candidiasis of vulva and vagina

Interventions

Intervention 1: Intervention I: vaginal use of Calendula Officinalis cream, one aplicator every night for 7 nights. Intervention 2: Intervention II: Vaginal use of Clotrimazole cream, one aplicator ev
Treatment - Drugs
Intervention I: vaginal use of Calendula Officinalis cream, one aplicator every night for 7 nights
Intervention II: Vaginal use of Clotrimazole cream, one aplicator every night for 7 nights

Sponsors

Research deputy of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: aged 18 to 45 years old; being married; diagnosis of candidiasis; single sexual partner; no history of allergy to drugs and plants; being literate; giving consent to participate in the study. Exclusion criteria: having any known chronic disease; use of any antibiotics and corticosteroids in the past two weeks; receiving antifungal drugs in the past 4 weeks; currently taking oral contraceptives; existence of other vaginal infections; any sores or lumps at the cervix; experience of severe stress over the past month; known Pregnancy; lactation; currently use of other herbal medicines; participation at another trial.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Response to the treatment. Timepoint: 10-15 days after the initiation of intervention. Method of measurement: Assessment of vaginal pH, direct observation, secretion culture.;Relapse of the infection. Timepoint: 30-35 days after the initiation of intervention. Method of measurement: Assessment of vaginal pH, direct observation, secretion culture.

Secondary

MeasureTime frame
Sexual function score. Timepoint: Before intervention, 30-35 days after the initation of therapy. Method of measurement: Female sexual function Index (FSFI).;Adverse events. Timepoint: 10-15 days after the initation of therapy. Method of measurement: Self-report.;Clinical complaints. Timepoint: Baseline, 10-15 and 30-35 days after initiation of intervention. Method of measurement: Self-report.;Client satisfaction. Timepoint: 10-15 and 30-35 days after the initation of intervention. Method of measurement: Self-report.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElnaz Saffari

Midwifery Department, Faculty of Nursing & Midwifery, Tabriz University of Medical Sciences

elnazsafari82@yahoo.com

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026